AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01261052 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Adaptive Proportional Derivative Algorithm
Description: The APD algorithm is based largely on a program that employs the Fading Memory Proportional Derivative (FMPD) insulin and glucagon infusion algorithm. The FMPD algorithm determines insulin and glucagon delivery rates based on proportional error, defined as the difference between the current glucose level and the target level, and the derivative error, defined as the rate of change of the glucose. The fading memory designation refers to weighting recent errors more heavily than remote errors.~The APD algorithm, like the FMPD algorithm, will determine insulin and glucagon infusion rates based on sensed glucose values and utilizes the derivative and proportional glucose error to determine delivery rates of insulin. However, the APD algorithm has a model predictive element which also leads to frequent measurement of tissue sensitivity to insulin.
Study NCT03401372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Oral doxycycline 100mg twice daily
Study NCT03401372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: 1.3mg/m2 of bortezomib on days 1, 8, 15 and 22 of a 35-day cycle
Study NCT03401372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.3mg/m2 of bortezomib on days 1, 8, 15 and 22 of a 35-day cycle
Study NCT03401372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 300mg/m2 cyclophosphamide on days 1, 8, 15 and 22 of a 35-day cycle
Study NCT03401372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300mg/m2 cyclophosphamide on days 1, 8, 15 and 22 of a 35-day cycle
Study NCT03401372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 40mg of dexamethasone on days 1, 8, 15 and 22 of a 35-day cycle
Study NCT03401372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40mg of dexamethasone on days 1, 8, 15 and 22 of a 35-day cycle
Study NCT04283500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Naloxone
Description: Participants will receive the BUP SL 32mg in divided doses rather than all at once. If after the initial 8mg dose a participant experiences over-sedation or another adverse event that would preclude further dosing, such as an allergic reaction, the subsequent dose will not be administered and the patient will be withdrawn from the study. The participant will be reassessed for other possible etiologies for these symptoms.
Study NCT02761005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eradication of H. pylori
Description: For the eradication of H. pylori, patients diagnosed to be infected with strain with mutation of 23S rRNA, their H. pylori strains are considered to be resistant to clarithromycin. Then, they are treated with vonoprazan 40 mg, metronidazole 500 mg and amoxicillin 1500 mg for 1 week. Patients diagnosed to be infected with strain without mutation of 23S rRNA, their H. pylori strains are considered to be resistant to clarithromycin. Then, they are treated with vonoprazan 40 mg, clarithromycin 400 mg and amoxicillin 1500 mg for 1 week.
Study NCT02392351 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal Denervation (Vessix)
Description: Percutaneous renal denervation using the Vessix Reduce™ Catheter and Vessix™ Generator
Study NCT02392351 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Renal Angiography
Description: Percutaneous renal angiography
Study NCT00963560 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReSTOR +3
Description: Bilateral implantation of the AcrySof ReSTOR Aspheric +3 Model SN6AD1 Intraocular lens (IOL) for the treatment of cataract.
Study NCT00963560 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Crystalens HD
Description: Bilateral implantation of the Crystalens HD intraocular lens (IOL) for the treatment of cataract.
Study NCT00963560 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Crystalens AO
Description: Bilateral implantation of the Crystalens AO intraocular lens (IOL) for the treatment of cataract.
Study NCT01851200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Intravenous Brentuximab Vedotin at the dose of 1.8 mg/Kg every 3 weeks until disease progression or onset of unacceptable toxicity
Study NCT04358289 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Basic antimicrobial stewardship education
Description: Commune health center: Revision of guidelines for antibiotic prescribing for respiratory infections in primary care, Training primary healthcare doctors in the application of the new guidelines
Study NCT04992585 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous transhepatic implantation of self-expandable metal stent
Description: A self-expandable metal stent is inserted into the extrahepatic bile duct which is obstructed by malignant disease
Study NCT04992585 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous transhepatic implantation of self-expandable metal stent
Description: A self-expandable metal stent is inserted into the extrahepatic bile duct which is obstructed by malignant disease
Study NCT03450434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC8 Oral Tablet
Description: 1 tablet of XC8 in a dose according to the treatment group + 2 tablets of placebo (in total 3 tablets) once daily in the morning during 12 weeks of treatment period.
Study NCT03450434 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo (in total 3 tablets) once daily in the morning during 12 weeks of treatment period.
Study NCT02721901 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iEAT Manual Intervention
Description: The iEAT manual guides caretakers in increasing the volume of food consumed by the child. The manual involves a touch screen application that collects and stores data on key behaviors and provides the feeder with direction for structuring treatment meals. Sessions will be 45 minutes long and occur biweekly for 10 sessions over 5 months. Two meals each day will be completed at home as part of the treatment of the feeding problems.
Study NCT02721901 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The psychoeducation condition will involve 6 appointments (once monthly for 5 months and 1 session during the post-treatment assessment). Each appointment will include curriculum related to feeding concerns such as the etiology of feeding problems, meal structure, appropriate food selection, mealtime problem behaviors, and generalization of appropriate feeding behaviors. Each session will last approximately 45 minutes.
Study NCT00044655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: As prescribed by routine prescriber (not dictated by study protocol)
Study NCT00044655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Description: As prescribed by routine prescriber (not dictated by study protocol)
Study NCT00044655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: As prescribed by routine prescriber (not dictated by study protocol)
Study NCT00044655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: As prescribed by routine prescriber (not dictated by study protocol)
Study NCT01745913 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS® CD34 Reagent System
Description: If a subject is randomized to the haplo-cord transplant group, their family member will undergo a stem cell collection. The stem cells from the haplo-identical donor will be purified by a procedure called CD34 selection before they are given to the subject. A special device called the CliniMACS® CD34 Reagent System, which is not FDA approved, will be used for this purpose. The manufacturer of the device, Miltenyi Biotec, is providing the researchers access to the device for use in this research study. Because the stem cells from the haplo-identical donor are treated using the CliniMACS CD34 selection device, they cells are considered investigational.
Study NCT01745913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine: 30 mg/m2 /day intravenously x 5 days total dose 150 mg/m2. Fludarabine will be dosed according to actual body weight
Study NCT01745913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: Fludarabine: 30 mg/m2 /day intravenously x 5 days total dose 150 mg/m2. Fludarabine will be dosed according to actual body weight
Study NCT01745913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan: 70mg/m2/day intravenously x 2 days. Melphalan will be dosed according to actual body weight. Cryotherapy with ice chips will be administered to prevent mucositis.
Study NCT01745913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Melphalan: 70mg/m2/day intravenously x 2 days. Melphalan will be dosed according to actual body weight. Cryotherapy with ice chips will be administered to prevent mucositis.
Study NCT01745913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit ATG
Description: Rabbit ATG (rATG): 1.5 mg/kg/day intravenously x 4 days, total 6 mg/kg. ATG will be dosed according to actual body weight. The first dose will be infused over at least six hours, and subsequent doses over at least 4 hours. Pre-medications include acetaminophen 650 mg by mouth, diphenhydramine 25-50 mg by mouth or intravenously, and methylprednisolone 2 mg/kg (1 mg/ kg at the initiation and 1 mg/kg half-way through anti-thymocyte globulin administration).
Study NCT01745913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabbit ATG
Description: Rabbit ATG (rATG): 1.5 mg/kg/day intravenously x 4 days, total 6 mg/kg. ATG will be dosed according to actual body weight. The first dose will be infused over at least six hours, and subsequent doses over at least 4 hours. Pre-medications include acetaminophen 650 mg by mouth, diphenhydramine 25-50 mg by mouth or intravenously, and methylprednisolone 2 mg/kg (1 mg/ kg at the initiation and 1 mg/kg half-way through anti-thymocyte globulin administration).
Study NCT01745913 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double Umbilical Cord Blood Transplantation
Description: All subjects will receive an UCB dose of > 3 x107/kg nucleated blood cells. It is expected that this will require co-infusion of two UCB in the large majority of cases. If two UCB are required, they will be at least 4/5 matched to the recipient.
Study NCT01745913 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Haplo-Identical Cord Transplantation
Description: If randomized to the haplo-cord group, a family member will undergo a stem cell collection. In both arms, subjects will receive a conditioning regimen prior to transplantation. The conditioning regimen utilized in this study incorporates fludarabine-Melphalan and antithymocyte globulin (ATG). This regimen has the advantage of being nearly identical to the regimen utilized for our haplo-cord regimen is based on the experience of the Dana-Farber/Mass-General regimen.
Study NCT03337867 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magstim Super Rapid2 System
Description: Intermittent theta-burst-stimulation (iTBS) protocol
Study NCT03337867 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Magstim Super Rapid2 System
Description: Sham stimulation
Study NCT04401150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Intravenous vitamin C administered in bolus doses of 50 mg/kg mixed in a 50-ml solution of either normal saline (0.9% NaCl) or dextrose 5% in water (D5W) during 30 to 60 minutes, every 6 hours for 96 hours (i.e. 200 mg/kg/day and 16 doses in total).
Study NCT04401150 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Dextrose 5% in water of normal saline (0.9% NaCL) in a volume to match vitamin C.
Study NCT01144169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HC)
Description: Subjects will receive HC orally for 14 days prior to surgery. The fixed dose of HC will be 400 mg/day in divided doses (200 mg bid). The final dose will be administered on the evening prior to nephrectomy.
Study NCT04247893 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: blood flow restriction
Description: Occlusion training is an exercise approach whereby resistance exercise or aerobic exercise is performed whilst an occlusion cuff is applied to proximal aspect of the muscle.
Study NCT04247893 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: blood flow restriction
Description: Occlusion training is an exercise approach whereby resistance exercise or aerobic exercise is performed whilst an occlusion cuff is applied to proximal aspect of the muscle.
Study NCT04247893 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: blood flow restriction
Description: Occlusion training is an exercise approach whereby resistance exercise or aerobic exercise is performed whilst an occlusion cuff is applied to proximal aspect of the muscle.
Study NCT04247893 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: Photobiomodulation therapy is defined as the utilization of non-ionizing electromagnetic energy to trigger photochemical changes within cellular structures that are receptive to photons.
Study NCT04247893 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo photobiomodulation
Description: Placebo photobiomodulation - photobiomodulation device turned off.
Study NCT04266392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-DCFPyl Ligand
Description: To assess the performance of \[18F\]-DCFPyl PET with whole-body MRI and multiparametric pelvic/prostate MRI for PCa detection in men with recurrence as determined by biochemical PSA level or evidence on CIM. Results of tracer uptake and MRI image features on whole body PET/MRI and dedicated pelvic/prostate PET/MRI, alone and together, will be correlated and compared to detection of lesions on CIM that usually includes bone scan (BS) and CT scan of the abdomen and pelvis, or PET imaging with F-18 Fluciclovine.In addition, in patients who undergo biopsy when performed as standard of care, we will correlate image features directly with histopathological findings on lesion biopsy to directly demonstrate that 'radiotracer and/or MRI positive' lesions contain tumor cells.
Study NCT01780844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASKP1240
Description: intravenous infusion
Study NCT01780844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: intravenous or oral
Study NCT01780844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: intravenous or oral
Study NCT01780844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF)
Description: intravenous or oral
Study NCT01780844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil (MMF)
Description: intravenous or oral
Study NCT01780844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: intravenous
Study NCT01780844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab
Description: intravenous
Study NCT01780844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisone
Description: Intravenous
Study NCT01780844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisone
Description: Intravenous
Study NCT01780844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral
Study NCT01780844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Oral
Study NCT01897727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Study NCT01897727 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: BP medication uptitration
Description: antihypertensive medication added or uptitrated following standard of care
Study NCT00958360 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interdisciplinary Low Vision Service
Description: Services are provided by optometrist(s) and low vision therapist(s), and include low vision therapy to improve use of remaining vision and low vision devices, and structured homework to practice use of low vision devices that are prescribed and dispensed.
Study NCT00958360 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basic Low Vision Service
Description: Service is provided by the optometrist alone and includes demonstration of low vision device use and maintenance of prescribed low vision devices, without low vision therapy or homework and with less contact time.
Study NCT02342860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WASH in Schools (WinS) programme
Description: The intervention group will receive the UNICEF/DFAT-supported WinS programme, which consists of the following intervention package:~* Hardware: water supply system, handwashing station for group handwashing, and gender-segregated toilets with one facility accessible to students with physical disabilities;~* Software: operations and maintenance (O\&M) training for teachers, hygiene training, and basic hygiene package.
Study NCT00395070 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allovectin-7®
Description: Allovectin-7® 2 mg intralesional injection into a single lesion weekly for six consecutive weeks, repeated beginning after each 8th week.
Study NCT00395070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine (DTIC)
Description: 1000 mg/m2 intravenous infusion over 60 minutes, repeated every 28 days, OR
Study NCT00395070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide (TMZ)
Description: 150 to 200 mg/m2 orally once daily for five consecutive days, repeated every 28 days.
Study NCT04657445 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: visual analogue scale
Description: A visual analog scale (VAS) is a measurement device used to quantify a subjective experience.
Study NCT02795624 — intervention group
Intervention type: PROCEDURE
Intervention: Spirometry
Description: Test is done to assess how well the lungs work by measuring how much air is inhaled, how much is exhaled, and how quickly it is exhaled.
Study NCT02795624 — intervention group
Intervention type: PROCEDURE
Intervention: Pulse Wave Analysis
Description: It is a non-invasive assessment of the pulse character
Study NCT02795624 — intervention group
Intervention type: PROCEDURE
Intervention: Peripheral arterial tonometry
Description: It is a non-invasive method to measure endothelial dysfunction.
Study NCT01921556 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: active comparator, QualiCCare education
Description: Physicians randomized into the intervention group get a QualiCCare training workshop designed to educate professionals on the guidelines but also and particularly governing professional behavior by feedback, reminders and pathways that help to change their attitudes and care behavior. Based on behavioral and learning theory, QualiCCare intervention not only tries to increase knowledge but also internal motivation and decision making by stimuli and resources and by written instruments that guide evidence based decision support.
Study NCT02016391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 0.4 µg/kg/hr infusion during RF procedure
Study NCT04245449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TEAACH
Description: TEAACH e-learning: 3-months of online educational modules include neuroscience education (based on an effective pain educational model37) to improve patient self-efficacy, and strategy-training38 to improve patients' problem-solving abilities for at-home arm use. The course is live on the MUSC MoodleCE platform.~TEAACH in-clinic therapy: 24 in-clinic sessions; 3 times/week for 4 weeks (month 1), 2 times/week for 4 weeks (month 2) and 1 time/week for 4 weeks (month 3) with 200 movement repetitions per session. In our RCTs, this therapy dose required \~1.0-1.5 hours/session. A critical element of TEAACH is the focus on linking in-clinic therapy to out-of-clinic real world paretic arm use via MoodleCE Learning Activities.
Study NCT02998879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velmanase Alfa (e.g. Lamazym)
Description: iv infusion treatment
Study NCT04931914 — intervention group
Intervention type: OTHER
Intervention: Clinical pharmacy sharing in the patient care regimen
Description: antibiotic regimens will be directed by a trained clinical pharmacist recommendation and supported by intensivist.
Study NCT01496287 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tube Delivery System (TDS)
Description: Placement of tympanostomy tube by the Acclarent tympanostomy tube delivery system under local anesthesia in an office/clinic setting
Study NCT00861757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: by mouth (PO), once daily (QD) (30 min after meal) for 12 weeks
Study NCT00861757 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PO, QD (30 min after meal) for 12 weeks
Study NCT00861757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: PO, QD (30 min after meal) for 12 weeks
Study NCT03569449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Family partners will keep records and communicate with families using standard information technology, including telephones, electronic medical records, and standard desktop software.